## Jared W Young

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8967973/publications.pdf

Version: 2024-02-01

147 6,034 43 papers citations h-index

154 154 154 5918 all docs docs citations times ranked citing authors

66

g-index

#	Article	IF	CITATIONS
1	EEG reveals that dextroamphetamine improves cognitive control through multiple processes in healthy participants. Neuropsychopharmacology, 2022, 47, 1029-1036.	5.4	6
2	MicroPET evidence for a hypersensitive neuroinflammatory profile of gp120 mouse model of HIV. Psychiatry Research - Neuroimaging, 2022, 321, 111445.	1.8	4
3	Amphetamine alters an EEG marker of reward processing in humans and mice. Psychopharmacology, 2022, 239, 923-933.	3.1	13
4	Combined Prior Chronic Methamphetamine Treatment and gp120 Expression Reduce PPI in Aged Male but not Female Mice. Neuroscience Letters, 2022, , 136639.	2.1	2
5	Preclinical Evaluation of Attention and Impulsivity Relevant to Determining ADHD Mechanisms and Treatments. Current Topics in Behavioral Neurosciences, 2022, , .	1.7	3
6	The Effects of Cannabis Use on Cognitive Function in Healthy Aging: A Systematic Scoping Review. Archives of Clinical Neuropsychology, 2021, 36, 673-685.	0.5	10
7	Moderate prenatal alcohol exposure impairs cognitive control, but not attention, on a rodent touchscreen continuous performance task. Genes, Brain and Behavior, 2021, 20, e12652.	2.2	19
8	Both HIV and Tat expression decrease prepulse inhibition with further impairment by methamphetamine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 106, 110089.	4.8	10
9	Chronic nicotine, but not suramin or resveratrol, partially remediates the mania-like profile of dopamine transporter knockdown mice. European Neuropsychopharmacology, 2021, 42, 75-86.	0.7	4
10	Convergent observations of MK-801-induced impairment in rat 5C-CPT performance across laboratories: reversal with a D1 but not nicotinic agonist. Psychopharmacology, 2021, 238, 979-990.	3.1	7
11	The relationship between cannabis use and cognition in people with bipolar disorder: A systematic scoping review. Psychiatry Research, 2021, 297, 113695.	3.3	5
12	Chronic antipsychotic treatment exerts limited effects on the mania-like behavior of dopamine transporter knockdown mice. Behavioural Brain Research, 2021, 405, 113167.	2.2	1
13	The Relationships between HIV-1 Infection, History of Methamphetamine Use Disorder, and Soluble Biomarkers in Blood and Cerebrospinal Fluid. Viruses, 2021, 13, 1287.	3.3	5
14	HIV Transgenic Rats Demonstrate Superior Task Acquisition and Intact Reversal Learning in the Within-Session Probabilistic Reversal Learning Task. Cognitive, Affective and Behavioral Neuroscience, 2021, 21, 1207-1221.	2.0	1
15	HIV Transgenic Rats Demonstrate Impaired Sensorimotor Gating But Are Insensitive to Cannabinoid (Î"9-Tetrahydrocannabinol)-Induced Deficits. International Journal of Neuropsychopharmacology, 2021, 24, 894-906.	2.1	6
16	Electrophysiological biomarkers of behavioral dimensions from cross-species paradigms. Translational Psychiatry, 2021, 11, 482.	4.8	20
17	Convergent neural substrates of inattention in bipolar disorder patients and dopamine transporterâ€deficient mice using the 5â€choice CPT. Bipolar Disorders, 2020, 22, 46-58.	1.9	21
18	The D2-family receptor agonist bromocriptine but, not nicotine, reverses NMDA receptor antagonist-induced working memory deficits in the radial arm maze in mice. Neurobiology of Learning and Memory, 2020, 168, 107159.	1.9	5

#	Article	IF	Citations
19	Sustained attention and vigilance deficits associated with HIV and a history of methamphetamine dependence. Drug and Alcohol Dependence, 2020, 215, 108245.	3.2	9
20	Short-active photoperiod gestation induces psychiatry-relevant behavior in healthy mice but a resiliency to such effects are seen in mice with reduced dopamine transporter expression. Scientific Reports, 2020, 10, 10217.	3.3	2
21	Converging evidence that short-active photoperiod increases acetylcholine signaling in the hippocampus. Cognitive, Affective and Behavioral Neuroscience, 2020, 20, 1173-1183.	2.0	6
22	Amphetamine improves rat 5-choice continuous performance test (5C-CPT) irrespective of concurrent low-dose haloperidol treatment. Psychopharmacology, 2020, 237, 1959-1972.	3.1	14
23	Btbd3 expression regulates compulsive-like and exploratory behaviors in mice. Translational Psychiatry, 2019, 9, 222.	4.8	17
24	Current status of the neurobiology of aggression and impulsivity. Neuropharmacology, 2019, 156, 107665.	4.1	1
25	Oxytocin improves probabilistic reversal learning but not effortful motivation in Brown Norway rats. Neuropharmacology, 2019, 150, 15-26.	4.1	17
26	The importance and depth of reproducibility in rodent models of psychiatric diseases. Pharmacology Biochemistry and Behavior, 2019, 178, 1-2.	2.9	5
27	Evidence for light-entrainment-induced switching between depression- & mania-relevant behaviors in mice. Neuropsychopharmacology, 2019, 44, 1679-1680.	5.4	3
28	Reconsidering the Latent Structure of Negative Symptoms in Schizophrenia: A Review of Evidence Supporting the 5 Consensus Domains. Schizophrenia Bulletin, 2019, 45, 725-729.	4.3	55
29	Phencyclidine increased while isolation rearing did not affect progressive ratio responding in rats: Investigating potential models of amotivation in schizophrenia. Behavioural Brain Research, 2019, 364, 413-422.	2.2	9
30	Dopamine transporter knockdown mice in the behavioral pattern monitor: A robust, reproducible model for mania-relevant behaviors. Pharmacology Biochemistry and Behavior, 2019, 178, 42-50.	2.9	15
31	The Effects of Cariprazine and Aripiprazole on PCP-Induced Deficits on Attention Assessed in the 5-Choice Serial Reaction Time Task. Psychopharmacology, 2018, 235, 1403-1414.	3.1	15
32	Mice with reduced DAT levels recreate seasonal-induced switching between states in bipolar disorder. Neuropsychopharmacology, 2018, 43, 1721-1731.	5.4	71
33	Understanding the Association Between Negative Symptoms and Performance on Effort-Based Decision-Making Tasks: The Importance of Defeatist Performance Beliefs. Schizophrenia Bulletin, 2018, 44, 1217-1226.	4.3	32
34	Reverse translated and gold standard continuous performance tests predict global cognitive performance in schizophrenia. Translational Psychiatry, 2018, 8, 80.	4.8	10
35	Relationship between effortful motivation and neurocognition in schizophrenia. Schizophrenia Research, 2018, 193, 69-76.	2.0	41
36	Amphetamine Modestly Improves Conners' Continuous Performance Test Performance in Healthy Adults. Journal of the International Neuropsychological Society, 2018, 24, 283-293.	1.8	26

#	Article	IF	Citations
37	Transgenic mice expressing HIV-1 envelope protein gp120 in the brain as an animal model in neuroAIDS research. Journal of NeuroVirology, 2018, 24, 156-167.	2.1	45
38	Cross-Species Neurophysiological Biomarkers of Attentional Dysfunction in Schizophrenia: Bridging the Translational Gap. Neuropsychopharmacology, 2018, 43, 230-231.	5 <b>.</b> 4	6
39	Nicotine improves probabilistic reward learning in wildtype but not alpha7 nAChR null mutants, yet alpha7 nAChR agonists do not improve probabilistic learning. European Neuropsychopharmacology, 2018, 28, 1217-1231.	0.7	4
40	Amphetamine improves mouse and human attention in the 5-choice continuous performance test. Neuropharmacology, 2018, 138, 87-96.	4.1	37
41	Cognitive Phenotypes for Biomarker Identification in Mental Illness: Forward and Reverse Translation. Current Topics in Behavioral Neurosciences, 2018, 40, 111-166.	1.7	7
42	The Fiveâ€Choice Continuous Performance Task (5Câ€CPT): A Crossâ€Species Relevant Paradigm for Assessment of Vigilance and Response Inhibition in Rodents. Current Protocols in Neuroscience, 2017, 78, 9.56.1-9.56.18.	2.6	23
43	Striatal dopamine D1 receptor suppression impairs reward-associative learning. Behavioural Brain Research, 2017, 323, 100-110.	2.2	23
44	Introduction to the special issue from the 2015 meeting of the International Behavioral Neuroscience Society. Neuroscience and Biobehavioral Reviews, 2017, 76, 185-186.	6.1	0
45	Animal to human translational paradigms relevant for approach avoidance conflict decision making. Behaviour Research and Therapy, 2017, 96, 14-29.	3.1	82
46	Adolescent GBR12909 exposure induces oxidative stress, disrupts parvalbumin-positive interneurons, and leads to hyperactivity and impulsivity in adult mice. Neuroscience, 2017, 345, 166-175.	2.3	10
47	Preclinical Models to Investigate Mechanisms of Negative Symptoms in Schizophrenia. Schizophrenia Bulletin, 2017, 43, 706-711.	4.3	13
48	Brexpiprazole reduces hyperactivity, impulsivity, and risk-preference behavior in mice with dopamine transporter knockdown—a model of mania. Psychopharmacology, 2017, 234, 1017-1028.	3.1	22
49	Neurophysiological Characterization of Attentional Performance Dysfunction in Schizophrenia Patients in a Reverse-Translated Task. Neuropsychopharmacology, 2017, 42, 1338-1348.	5.4	23
50	Blockade of dopamine D $<$ sub $>$ 1 $<$ /sub $>$ -family receptors attenuates the mania-like hyperactive, risk-preferring, and high motivation behavioral profile of mice with low dopamine transporter levels. Journal of Psychopharmacology, 2017, 31, 1334-1346.	4.0	16
51	The 5 choice continuous performance test (5C-CPT): A novel tool to assess cognitive control across species. Journal of Neuroscience Methods, 2017, 292, 53-60.	2.5	30
52	Modafinil improves attentional performance in healthy, non-sleep deprived humans at doses not inducing hyperarousal across species. Neuropharmacology, 2017, 125, 254-262.	4.1	17
53	The COMT Val158Met Polymorphism and Exploratory Behavior in Bipolar Mania. Molecular Neuropsychiatry, 2017, 3, 151-156.	2.9	6
54	Research Domain Criteria versus DSM V: How does this debate affect attempts to model corticostriatal dysfunction in animals?. Neuroscience and Biobehavioral Reviews, 2017, 76, 301-316.	6.1	21

#	Article	IF	CITATIONS
55	The effects of reduced dopamine transporter function and chronic lithium on motivation, probabilistic learning, and neurochemistry in mice: Modeling bipolar mania. Neuropharmacology, 2017, 113, 260-270.	4.1	28
56	Tolcapone-Enhanced Neurocognition in Healthy Adults: Neural Basis and Predictors. International Journal of Neuropsychopharmacology, 2017, 20, 979-987.	2.1	18
57	Animal Models of Bipolar Disorder. , 2017, , 263-267.		O
58	The mood stabilizer valproic acid opposes the effects of dopamine on circadian rhythms. Neuropharmacology, 2016, 107, 262-270.	4.1	37
59	Effect of 5-HT2A and 5-HT2C receptors on temporal discrimination by mice. Neuropharmacology, 2016, 107, 364-375.	4.1	34
60	Modeling neurodevelopmental cognitive deficits in tasks with crossâ€species translational validity. Genes, Brain and Behavior, 2016, 15, 27-44.	2.2	36
61	Premature responses in the five-choice serial reaction time task reflect rodents' temporal strategies: evidence from no-light and pharmacological challenges. Psychopharmacology, 2016, 233, 3513-3525.	3.1	45
62	Differences in the performance of NK1Râ^'/â^' (†knockout') and wildtype mice in the 5†Choice Continuous Performance Test. Behavioural Brain Research, 2016, 298, 268-277.	2.2	13
63	Perseveration by NK1R-/- ( knockout') mice is blunted by doses of methylphenidate that affect neither other aspects of their cognitive performance nor the behaviour of wild-type mice in the 5-Choice Continuous Performance Test. Journal of Psychopharmacology, 2016, 30, 837-847.	4.0	12
64	Amphetamine increases activity but not exploration in humans and mice. Psychopharmacology, 2016, 233, 225-233.	3.1	33
65	Locomotor Profiling from Rodents to the Clinic and Back Again. Current Topics in Behavioral Neurosciences, 2015, 28, 287-303.	1.7	23
66	Methamphetamine Exposure Combined with HIV-1 Disease or gp120 Expression: Comparison of Learning and Executive Functions in Humans and Mice. Neuropsychopharmacology, 2015, 40, 1899-1909.	5.4	42
67	Negative affective states and cognitive impairments in nicotine dependence. Neuroscience and Biobehavioral Reviews, 2015, 58, 168-185.	6.1	71
68	GlyT-1 Inhibition Attenuates Attentional But Not Learning or Motivational Deficits of the Sp4 Hypomorphic Mouse Model Relevant to Psychiatric Disorders. Neuropsychopharmacology, 2015, 40, 2715-2726.	5.4	33
69	Restoration of <i>Sp4</i> in Forebrain GABAergic Neurons Rescues Hypersensitivity to Ketamine in <i>Sp4</i> Hypomorphic Mice. International Journal of Neuropsychopharmacology, 2015, 18, pyv063.	2.1	4
70	Introduction to the special issue from the 2014 meeting of the International Behavioral Neuroscience Society. Neuroscience and Biobehavioral Reviews, 2015, 58, 1-3.	6.1	2
71	Early Adolescent Emergence of Reversal Learning Impairments in Isolation-Reared Rats. Developmental Neuroscience, 2015, 37, 253-262.	2.0	23
72	Cognitive deficits associated with combined HIV gp120 expression and chronic methamphetamine exposure in mice. European Neuropsychopharmacology, 2015, 25, 141-150.	0.7	37

#	Article	IF	Citations
73	Developing treatments for cognitive deficits in schizophrenia: The challenge of translation. Journal of Psychopharmacology, 2015, 29, 178-196.	4.0	95
74	Neural mechanisms regulating different forms of risk-related decision-making: Insights from animal models. Neuroscience and Biobehavioral Reviews, 2015, 58, 147-167.	6.1	125
75	Effort-Based Decision-Making Paradigms for Clinical Trials in Schizophrenia: Part 2—External Validity and Correlates. Schizophrenia Bulletin, 2015, 41, 1055-1065.	4.3	95
76	Translational Rodent Paradigms to Investigate Neuromechanisms Underlying Behaviors Relevant to Amotivation and Altered Reward Processing in Schizophrenia. Schizophrenia Bulletin, 2015, 41, 1024-1034.	4.3	43
77	Modeling bipolar disorder in mice by increasing acetylcholine or dopamine: chronic lithium treats most, but not all features. Psychopharmacology, 2015, 232, 3455-3467.	3.1	29
78	Effort-Based Decision-Making Paradigms for Clinical Trials in Schizophrenia: Part 1â€"Psychometric Characteristics of 5 Paradigms. Schizophrenia Bulletin, 2015, 41, 1045-1054.	4.3	137
79	Investigating the mechanism(s) underlying switching between states in bipolar disorder. European Journal of Pharmacology, 2015, 759, 151-162.	3.5	57
80	Negative visuospatial priming in isolation-reared rats: Evidence of resistance to the disruptive effects of amphetamine. Cognitive, Affective and Behavioral Neuroscience, 2015, 15, 901-914.	2.0	3
81	Investigating the underlying mechanisms of aberrant behaviors in bipolar disorder from patients to models. Neuroscience and Biobehavioral Reviews, 2015, 58, 4-18.	6.1	25
82	Dispatches from the International Behavioral Neuroscience Society meeting 2014. Behavioural Brain Research, 2015, 295, 1-2.	2.2	0
83	The catecholaminergic–cholinergic balance hypothesis of bipolar disorder revisited. European Journal of Pharmacology, 2015, 753, 114-126.	3.5	81
84	Translational and Early Phase Strategies for Treatment Development: Report of ISCTM Autumn 2013 Symposium. Innovations in Clinical Neuroscience, 2015, 12, 5S-10S.	0.1	2
85	Altered exploration and sensorimotor gating of the chakragati mouse model of schizophrenia Behavioral Neuroscience, 2014, 128, 460-467.	1.2	8
86	Inhibition of protein translation by the DISC1-Boymaw fusion gene from a Scottish family with major psychiatric disorders. Human Molecular Genetics, 2014, 23, 5683-5705.	2.9	31
87	Prepulse inhibition in HIV-1 gp120 transgenic mice after withdrawal from chronic methamphetamine. Behavioural Pharmacology, 2014, 25, 12-22.	1.7	31
88	Isolation rearing effects on probabilistic learning and cognitive flexibility in rats. Cognitive, Affective and Behavioral Neuroscience, 2014, 14, 388-406.	2.0	66
89	Sleep deprivation impairs performance in the 5-choice continuous performance test: Similarities between humans and mice. Behavioural Brain Research, 2014, 261, 40-48.	2.2	49
90	Reduced Dopamine Transporter Functioning Induces High-Reward Risk-Preference Consistent with Bipolar Disorder. Neuropsychopharmacology, 2014, 39, 3112-3122.	5.4	78

#	Article	IF	CITATIONS
91	Dopamine depletion attenuates some behavioral abnormalities in a hyperdopaminergic mouse model of bipolar disorder. Journal of Affective Disorders, 2014, 155, 247-254.	4.1	41
92	Differential effects of dopamine transporter inhibitors in the rodent lowa gambling task. Psychopharmacology, 2013, 225, 661-674.	3.1	54
93	Further evidence for Clockî"19 mice as a model for bipolar disorder mania using cross-species tests of exploration and sensorimotor gating. Behavioural Brain Research, 2013, 249, 44-54.	2.2	42
94	Cognitive performance and response inhibition in developmentally vitamin D (DVD)-deficient rats. Behavioural Brain Research, 2013, 242, 47-53.	2.2	55
95	Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia. Biochemical Pharmacology, 2013, 86, 1122-1132.	4.4	112
96	A novel visuospatial priming task for rats with relevance to Tourette syndrome and modulation of dopamine levels. Neuroscience and Biobehavioral Reviews, 2013, 37, 1139-1149.	6.1	21
97	Bridging the bench to bedside gap: validation of a reverse-translated rodent continuous performance test using functional magnetic resonance imaging. Psychiatry Research - Neuroimaging, 2013, 212, 183-191.	1.8	32
98	Inhibitory deficits in euthymic bipolar disorder patients assessed in the human behavioral pattern monitor. Journal of Affective Disorders, 2013, 150, 948-954.	4.1	31
99	Short-Term Recognition Memory Correlates with Regional CNS Expression of microRNA-138 in Mice. American Journal of Geriatric Psychiatry, 2013, 21, 461-473.	1.2	35
100	Consideration of species differences in developing novel molecules as cognition enhancers. Neuroscience and Biobehavioral Reviews, 2013, 37, 2181-2193.	6.1	35
101	Nicotinic agonist-induced improvement of vigilance in mice in the 5-choice continuous performance test. Behavioural Brain Research, 2013, 240, 119-133.	2.2	67
102	Measuring the construct of executive control in schizophrenia: Defining and validating translational animal paradigms for discovery research. Neuroscience and Biobehavioral Reviews, 2013, 37, 2125-2140.	6.1	68
103	Demand and modality of directed attention modulate "pre-attentive―sensory processes in schizophrenia patients and nonpsychiatric controls. Schizophrenia Research, 2013, 146, 326-335.	2.0	53
104	Animal models of working memory: A review of tasks that might be used in screening drug treatments for the memory impairments found in schizophrenia. Neuroscience and Biobehavioral Reviews, 2013, 37, 2111-2124.	6.1	107
105	Behavioral effects of chronic methamphetamine treatment in HIV-1 gp120 transgenic mice. Behavioural Brain Research, 2013, 236, 210-220.	2.2	27
106	Chronic valproate attenuates some, but not all, facets of mania-like behaviour in mice. International Journal of Neuropsychopharmacology, 2013, 16, 1021-1031.	2.1	45
107	Reward learning as a potential target for pharmacological augmentation of cognitive remediation for schizophrenia: a roadmap for preclinical development. Frontiers in Neuroscience, 2013, 7, 103.	2.8	23
108	Prolonged Ketamine Effects in Sp4 Hypomorphic Mice: Mimicking Phenotypes of Schizophrenia. PLoS ONE, 2013, 8, e66327.	2.5	27

#	Article	IF	CITATIONS
109	Rats tested after a washout period from sub-chronic PCP administration exhibited impaired performance in the 5-Choice Continuous Performance Test (5C-CPT) when the attentional load was increased. Neuropharmacology, 2012, 62, 1432-1441.	4.1	59
110	Mouse pharmacological models of cognitive disruption relevant to schizophrenia. Neuropharmacology, 2012, 62, 1381-1390.	4.1	32
111	Hippocampal calbindin-1 immunoreactivity correlate of recognition memory performance in aged mice. Neuroscience Letters, 2012, 516, 161-165.	2.1	32
112	Four factors underlying mouse behavior in an open field. Behavioural Brain Research, 2012, 233, 55-61.	2.2	77
113	Behavioral Animal Models to Assess Pro-cognitive Treatments for Schizophrenia. Handbook of Experimental Pharmacology, 2012, , 39-79.	1.8	24
114	Examining the genetic and neural components of cognitive flexibility using mice. Physiology and Behavior, 2012, 107, 666-669.	2.1	13
115	Attentional Processing in C57BL/6J Mice Exposed to Developmental Vitamin D Deficiency. PLoS ONE, 2012, 7, e35896.	2.5	31
116	D1 receptor activation improves vigilance in rats as measured by the 5-choice continuous performance test. Psychopharmacology, 2012, 220, 129-141.	3.1	44
117	Working memory span capacity improved by a D2 but not D1 receptor family agonist. Behavioural Brain Research, 2011, 219, 181-188.	2.2	27
118	The effect of reduced dopamine D4 receptor expression in the 5-choice continuous performance task: Separating response inhibition from premature responding. Behavioural Brain Research, 2011, 222, 183-192.	2.2	72
119	Increased risk-taking behavior in dopamine transporter knockdown mice: further support for a mouse model of mania. Journal of Psychopharmacology, 2011, 25, 934-943.	4.0	95
120	Repeated Assessment of Exploration and Novelty Seeking in the Human Behavioral Pattern Monitor in Bipolar Disorder Patients and Healthy Individuals. PLoS ONE, 2011, 6, e24185.	2.5	44
121	Predictive animal models of mania: hits, misses and future directions. British Journal of Pharmacology, 2011, 164, 1263-1284.	5.4	117
122	Delayed procedural learning in $\hat{l}_{\pm}$ 7-nicotinic acetylcholine receptor knockout mice. Genes, Brain and Behavior, 2011, 10, 720-733.	2.2	81
123	Initial evidence linking synaptic superoxide production with poor short-term memory in aged mice. Brain Research, 2011, 1368, 65-70.	2.2	32
124	Effect of methamphetamine dependence on inhibitory deficits in a novel human open-field paradigm. Psychopharmacology, 2011, 215, 697-707.	3.1	31
125	Factor analysis of attentional set-shifting performance in young and aged mice. Behavioral and Brain Functions, 2011, 7, 33.	3.3	10
126	Dopamine Receptor Mediation of the Exploratory/Hyperactivity Effects of Modafinil. Neuropsychopharmacology, 2011, 36, 1385-1396.	5.4	46

#	Article	IF	CITATIONS
127	Age-associated improvements in cross-modal prepulse inhibition in mice Behavioral Neuroscience, 2010, 124, 133-140.	1.2	27
128	The mouse attentional-set-shifting task: A method for assaying successful cognitive aging?. Cognitive, Affective and Behavioral Neuroscience, 2010, 10, 243-251.	2.0	65
129	GBR 12909 administration as a mouse model of bipolar disorder mania: mimicking quantitative assessment of manic behavior. Psychopharmacology, 2010, 208, 443-454.	3.1	71
130	The mania-like exploratory profile in genetic dopamine transporter mouse models is diminished in a familiar environment and reinstated by subthreshold psychostimulant administration. Pharmacology Biochemistry and Behavior, 2010, 96, 7-15.	2.9	56
131	The quantitative assessment of motor activity in mania and schizophrenia. Journal of Affective Disorders, 2010, 120, 200-206.	4.1	84
132	Cross-species assessments of motor and exploratory behavior related to bipolar disorder. Neuroscience and Biobehavioral Reviews, 2010, 34, 1296-1306.	6.1	58
133	Action of Modafinilâ€"Increased Motivation Via the Dopamine Transporter Inhibition and D1 Receptors?. Biological Psychiatry, 2010, 67, 784-787.	1.3	72
134	Quantifying over-activity in bipolar and schizophrenia patients in a human open field paradigm. Psychiatry Research, 2010, 178, 84-91.	3.3	69
135	Evaluation of the clinical efficacy of asenapine in schizophrenia. Expert Opinion on Pharmacotherapy, 2010, 11, 2107-2115.	1.8	23
136	Animal Models of Schizophrenia. Current Topics in Behavioral Neurosciences, 2010, 4, 391-433.	1.7	75
137	Dopamine D1 and D2 Receptor Family Contributions to Modafinil-Induced Wakefulness. Journal of Neuroscience, 2009, 29, 2663-2665.	3.6	28
138	A Reverse-Translational Study of Dysfunctional Exploration in Psychiatric Disorders. Archives of General Psychiatry, 2009, 66, 1072.	12.3	174
139	Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia., 2009, 122, 150-202.		285
140	Asenapine effects in animal models of psychosis and cognitive function. Psychopharmacology, 2009, 206, 699-714.	3.1	41
141	Progressive impairment in olfactory working memory in a mouse model of Mild Cognitive Impairment. Neurobiology of Aging, 2009, 30, 1430-1443.	3.1	55
142	The 5-Choice Continuous Performance Test: Evidence for a Translational Test of Vigilance for Mice. PLoS ONE, 2009, 4, e4227.	2.5	159
143	Atypical antipsychotics clozapine and quetiapine attenuate prepulse inhibition deficits in dopamine transporter knockout mice. Behavioural Pharmacology, 2008, 19, 562-565.	1.7	53
144	The odour span task: A novel paradigm for assessing working memory in mice. Neuropharmacology, 2007, 52, 634-645.	4.1	58

#	Article	IF	CITATIONS
145	Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice. European Neuropsychopharmacology, 2007, 17, 145-155.	0.7	203
146	A reverse-translational approach to bipolar disorder: Rodent and human studies in the Behavioral Pattern Monitor. Neuroscience and Biobehavioral Reviews, 2007, 31, 882-896.	6.1	104
147	Nicotine Improves Sustained Attention in Mice: Evidence for Involvement of the α7 Nicotinic Acetylcholine Receptor. Neuropsychopharmacology, 2004, 29, 891-900.	5.4	204